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and compared with log-rank tests.Since June 1993 until 
March 2013, 87 patients with the diagnosis of gallbladder 
cancer who underwent extended or simple cholecystectomy 
and were staged as T1b-2-3N0-1M0, received adjuvant radio-
chemotherapy at Instituto Oncológico, Viña del Mar. Overall 
survival and median survival were analyzed in relation to 
different prognostic factors, using Kaplan-Meier techniques 
and compared with log-rank tests. 
Results: With a median follow-up of 43 months (range: 5-180 
months) the 5 and 10-year overall survival (OS) rate for the 
entire cohort was 44.9% and 36.8%, respectively, and the 
median survival time was 45 months. In the group who 
underwent extended cholecystectomy, the 5-year OS was 
57.2% versus 31.2% for those who underwent simple 
cholecystectomy (p=0.032). The median survival time was 57 
and 27 months for patients with extended cholecystectomy 
and simple cholecystectomy, respectively (p=0.032).  
Conclusions: After a complete resection, radio-
chemotherapy appears a good approach and can achieve a 
long term survival rate. This benefit is higher for those in 
which surgery is an extended cholecystectomy.  
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Purpose/Objective: A clinical data registry was required to 
support the data requirements of the UK patients undergoing 
rectal brachytherapy. The data input and access 
requirements for this group culminated in the need for a 
bespoke development rather than an off-the-shelf product. 
These extended requirements included the need to allow 
patient-led data entry, multi-centre access, discussion 
forums, customised data extraction and visualisation. 
Materials and Methods: A bespoke, extendable and 
customisable web-based clinical data repository system was 
developed. Case report forms were translated into web-
enabled forms either by a specially implemented form 
designer or via consultation with the developer. Patient-led 
data entry is achieved by allowing data managers to assign 
each case a patient login. Patients are able to enter data on 
baseline and follow-up assessments via a simple web 
interface or tablet App before or during consultation. The 
registry has been designed to allow multi-centre data input 
while allowing doctors from disparate centres to be given 
permission to view other centres cases. Security of data is 
ensured by separation of the web server from the data 
server, secure certificates and user accounts with group 
assignments. All events that occur on the registry are logged 
in encrypted tables allowing audit trails to be tracked. 
Results: An extendible web-enabled database has been 
developed which allows a bespoke and advanced data 
registry to be developed and deployed relatively rapidly. A 
unique feature of this registry system is patient-led data 
entry. Patients are reminded by email to enter data shortly 
before follow-up appointments and are able to utilise the 
web interface or tablet Apps. Additionally, a focus has been 
placed on the ability to extract customised data reports and 
visualisation reports without the need for statistical 
packages. This feature allows varying questions to be asked 
of the registry directly via the web interface. 
Conclusions: Existing clinical trial and clinical registry 
systems have been evaluated for suitability for this trial. 
Some of the systems evaluated were more oriented to clinical 
trial management than needed for the current requirements 
and others were restricted in the patient-led data entry and 
data visualisation. These finding led to the development of a 
customisable data registry system, which is able to support 
multiple clinical registries and requirements. New registries 
can be set-up with relative simplicity by utilising built-in 
form and report designers tools. Patient-led entry enables a 
greater emphasis to be placed on survivorship which is very 
important in this patient-centred treatment approach. 
With thanks to BRIGHT charity for initial funding support. 
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Purpose/Objective: While for locally-advanced (T3-T4) 
tumors, the combination of elective lymph-node irradiation 
along with concomitant chemotherapy (CT) has been 
demonstrated to improve loco-regional control (LRC) 
compared to radiotherapy (RT) alone, the best treatment 
strategy remains controversial in early-stage anal tumors (T1-
T2) without nodal involvement. The role of prophylactic 
inguinal irradiation (PII) in this setting remains an open issue, 
especially in the era of modern EBRT techniques. The aim of 
this study was to assess outcomes and toxicity results of 
highly-conformal EBRT techniques in patients with early-
stage T1-2 N0 anal cancers measuring < 3 cm and involving < 
50% of the anal circumference treated conservatively with or 
without concomitant CT. 
Materials and Methods: Data of 44 patients with cT1 (n=13) 
or cT2 <3 cm, involving < 50% of the anal circumference (n= 
31, median size 2.5 cm) cN0, histologically proven anal 
carcinoma, treated in two institutions between 03/2006 and 
04/2014 were retrospectively reviewed. Median age was 61 
years (range: 36-87). For all patients, the pelvis and inguinal 
region were treated with highly conformal EBRT techniques, 
including helical Tomotherapy, intensity-modulated radiation 
therapy (IMRT) or volumetric modulated arc therapy (VMAT) 
in 22, 17 and 5 patients, respectively. Regarding the boost, 
28 patients were treated with 3D-conformal RT, 6 with 
Tomotherapy, 4 with IMRT and 6 with VMAT. Image-guided RT 
modalities were used for daily repositioning. EBRT schedule 
consisted of elective lymph node irradiation including PII to 
36 Gy (1.8 Gy/fraction), followed by a boost to the GTV up to 
59.4 Gy after a median gap of 10 days (range: 1-26). 
Concomitant CT was delivered in 37 patients (Mitomycin/5-
FU and Mitomycin/Capecitabine for 25 and 9 patients, 
respectively). Toxicity was scored according to the CTCAE 
v3.0 scale. 
Results: Treatments were delivered in all patients as 
planned, with no interruptions. After a median follow-up of 
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38 months (range: 2-95), 4 patients (9.1%) had a local relapse 
(LR) after a median time of 10 months (range: 1-26). All 
relapses occurred in T2 tumors, with 3 out of 4 presenting 
with an initial tumor size > 2.5 cm. No nodal or metastatic 
progression were observed. The actuarial 4-year LR free-
survival and colostomy free-survival were 88.7%. Overall, 5 
cases of acute grade 3 skin toxicity (4 perianal and 1 inguinal) 
and 4 cases of acute grade 3 diarrhoea were observed. No 
late grade ≥ 3 toxicity was reported. 
Conclusions: In early stage node negative anal cancers (T1-2 
measuring ≤3cm, with ≤ 50% anal circumference 
involvement), highly conformal RT techniques provide 
excellent LRC rates with an acceptable toxicity profile, at 
least comparable to those published in the literature, 
especially using a brachytherapy boost. PII to 36 Gy delivered 
with modern EBRT techniques may significantly reduce the 
risk of inguinal relapse without increasing radiation-induced 
side effects.  
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Purpose/Objective: This retrospective study evaluates the 
utility of a 3-Tesla (3T) MRI in detecting a local recurrence or 
nodal involvement in post-prostatectomy prostate cancer 
patients receiving adjuvant or salvage intensity modulated 
radiation therapy (IMRT). 
Materials and Methods: From 1/1/2006 to 5/1/2012, 90 
patients status post prostatectomy had a 3T MRI prior to 
adjuvant or salvage IMRT. Patients were grouped into those 
with positive and negative findings on MRI. The following 
variables were analyzed for their usefulness in predicting 
positive findings on MRI: pre- and post-op PSA, PSA and 
testosterone at time of imaging, PSA velocity, surgical 
margins, Gleason grade, stage, physical exam findings, and 
type of surgical prostatectomy. 
Results: Significant variables predictive of a positive MRI 
included positive margins and presence of a positive digital 
rectal exam. Furthermore, the anatomical site of tumor 
recurrence on 3T MRI was significantly associated with the 
anatomical locations of positive margins. In the vast majority 
of patients with a positive 3T MRI, imaging aided in IMRT 
treatment planning. Patients with a positive MRI finding, as 
compared without MRI findings, did not show differences in 
clinical outcome at follow-up. 
Conclusions: A pre-RT 3T MRI is useful to assess recurrences 
in prostate cancer in post-prostatectomy men with rising PSA 
levels. In order to ensure cost-effectiveness of the 3T MRI, 
assessment of tumor margins and a careful physical 
examination must be performed in order to optimize the 
chance of a positive MRI finding and thus guide treatment 
planning.  
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Purpose/Objective: The role of 18F-choline positron emission 
tomography/computed tomography (Cho- PET) in diagnosis 
and staging before definitive radiotherapy in localized 
prostate cancer patients is not standardized. Aim of the 
study is to evaluate the impact of Cho- PET decision making 
strategy in patients with localized prostate cancer eligible to 
definitive radiotherapy. 
Materials and Methods: From January 2011 to August 2014, 
sixty patients with biopsy proven prostate adenocarcinoma, 
with no prior treatment on primary tumor and staged with 
Cho-PET before radiotherapy were prospectively enrolled. 
Median age was 73 years (60-81 years); Gleason score was 6 
in 32 patients (pts), 7 in 14 pts and ≥8 in 14 pts; median PSA 
value at the diagnosis was 6.79 ng/ml (2.3-143ng/ml). All 
patients were treated with Volumetric Modulated Arc 
Therapy (Varian RapidArc®, Palo Alto - CA, USA) with 
simultaneous integrated boost in 28-30 fractions (moderate 
hypofractionation) as follow: for low risk prostate PTV only, 
for intermediate risk prostate and seminal vesicles PTVs and 
for high risk prostate, seminal vesicles and pelvic lymph 
nodes. Androgen deprivation was prescribed according to 
NCCN risk classification. Cho-PET findings were used to 
define the stage according to the detection of primary tumor 
(T), pelvic lymph nodes (N) and distant metastases (M). 
Therapeutic strategy based on the Cho-PET evaluation was 
compared to the strategy that would have been proposed in 
case of PET not available and/or not strictly indicated, 
following international and national prostate cancer 
guidelines. 
Results: Cho-PET was positive in 57 cases (95%): T (prostate 
gland only) in 46 (81% of all positive cases); T in combination 
with N( pelvic nodes) in 7 (12.5%); and M(bone) in 
combination with T or N, or both, in 4 (6.5%). After the Cho-
PET patients were stratified according to NCCN risk 
classification as follows: 26 (43%) low risk, 10 (16%) 
intermediate risk and 24 (41%) high risk. Cho-PET shifted 
treatment indication in 13 cases (21%). The changes 
regarding radiation treatment volumes were as follow: 6 
intermediate risk pts (10%) shifted to high risk and 
consequently were irradiated on prostate, seminal vesicles 
and pelvic nodes PTVs; in 7 high risk pts (11%) the Cho-PET 
showed bone and/or pelvic lymph node uptake and 
consequently a simultaneous integrated boost on PET positive 
